Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy

Franceschi, Silvia; Maso, Luigino Dal; Rickenbach, Martin; Polesel, Jerry; Hirschel, Bernard; Cavassini, Matthias; Bordoni, Andrea; Elzi, Luigia; Ess, Silvia; Jundt, Gernot; Mueller, Nicolas J.; Clifford, Gary M.

doi:10.1038/sj.bjc.6604520

Cited by 129 publications

(73 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding that cART had little effect on HL is another clear difference with respect to KS 30 and NHL. 27 Equally, a history of AIDS diagnosis, which has often been used as proxy of immunodeficiency, did not significantly predict HL risk, as also shown previously.…”

Section: Discussionmentioning

confidence: 82%

Hodgkin lymphoma in the Swiss HIV Cohort Study

Clifford

Rickenbach

Lise

et al. 2009

Blood

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) risk is elevated among persons infected with HIV (PHIV)and has been suggested to have increased in the era of combined antiretroviral therapy (cART). Among 14 606 PHIV followed more than 20 years in the Swiss HIV Cohort Study (SHCS), determinants of HL were investigated using 2 different approaches, namely, a cohort and nested case-control study, estimating hazard ratios (HRs) and matched odds ratios, re-

show abstract

Section: Discussionmentioning

confidence: 82%

Hodgkin lymphoma in the Swiss HIV Cohort Study

Clifford

Rickenbach

Lise

et al. 2009

Blood

View full text Add to dashboard Cite

show abstract

“…Compared to its prevalence in the 1980s and early 1990s, the rate of Kaposi's sarcoma was relatively low (19). Among the HIV-infected patients, MSM were the most affected by Kaposi's sarcoma.…”

Section: Discussionmentioning

confidence: 99%

Mucocutaneous manifestations and the relationship to CD4 lymphocyte counts among Turkish HIV/AIDS patients in İstanbul, Turkey

Aydın¹,

Karaosmanoğlu²,

Özeren³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: Dermatologic findings differ among countries but no sufficient data about Turkish HIV-infected patients exist in the literature. Therefore, our aim in this study was to document the dermatologic manifestations and their relationships with CD4 cell counts among HIV/AIDS patients visiting our clinic for the first time in İstanbul, Turkey. Materials and methods:A retrospective analysis of 306 HIV/AIDS patients (260 men, mean age: 38.3 years) was done in a tertiary hospital in İstanbul from January 2006 to September 2012. Information on age, sex, transmission routes, socioeconomic and educational status, CD4 counts, and dermatologic findings was collected retrospectively from medical records. Results:Our analyses revealed at least 1 dermatologic disease in 111 of the 306 (36.2%) patients. Mean CD4 count of the patients was 393.64 cells/mm3 (range: 4-1270 cells/mm 3 ). Oral candidiasis (12.4%), herpes zoster (5.9%), dermatophytosis (5.4%), hyperpigmentation (5.2%), and folliculitis (4.6%) were the most common skin problems. Statistically significant correlation (P < 0.05) with low CD4 cell counts was found for oral candidiasis, folliculitis, herpes zoster, hyperpigmentation, xerosis, and Kaposi's sarcoma. Conclusion:Dermatologic manifestations in this study were identical to those described in most studies from Asia, and there were more manifestations as the HIV infection progressed and immune functions declined.

show abstract

“…For example, in HIV, Kaposi sarcoma risk is strongly inversely associated with CD4 ϩ T-cell count. 41,42 In CVID, however, only a small subset (Ͻ 10%) of patients appear to have very low CD4 counts. 43 A final possibility is that Ig-replacement therapy, used in 71% of the cohort, 15 is associated with a reduced risk of cancer in PID.…”

Section: Discussionmentioning

confidence: 99%